| pubmed-article:15749921 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:15749921 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:15749921 | lifeskim:mentions | umls-concept:C1332717 | lld:lifeskim |
| pubmed-article:15749921 | lifeskim:mentions | umls-concept:C1706438 | lld:lifeskim |
| pubmed-article:15749921 | lifeskim:mentions | umls-concept:C0936223 | lld:lifeskim |
| pubmed-article:15749921 | lifeskim:mentions | umls-concept:C0039194 | lld:lifeskim |
| pubmed-article:15749921 | lifeskim:mentions | umls-concept:C0011306 | lld:lifeskim |
| pubmed-article:15749921 | lifeskim:mentions | umls-concept:C0085358 | lld:lifeskim |
| pubmed-article:15749921 | lifeskim:mentions | umls-concept:C0087071 | lld:lifeskim |
| pubmed-article:15749921 | lifeskim:mentions | umls-concept:C1704632 | lld:lifeskim |
| pubmed-article:15749921 | lifeskim:mentions | umls-concept:C0871261 | lld:lifeskim |
| pubmed-article:15749921 | lifeskim:mentions | umls-concept:C1332714 | lld:lifeskim |
| pubmed-article:15749921 | lifeskim:mentions | umls-concept:C1413244 | lld:lifeskim |
| pubmed-article:15749921 | lifeskim:mentions | umls-concept:C2698600 | lld:lifeskim |
| pubmed-article:15749921 | lifeskim:mentions | umls-concept:C2911692 | lld:lifeskim |
| pubmed-article:15749921 | lifeskim:mentions | umls-concept:C1706817 | lld:lifeskim |
| pubmed-article:15749921 | pubmed:issue | 6 | lld:pubmed |
| pubmed-article:15749921 | pubmed:dateCreated | 2005-3-7 | lld:pubmed |
| pubmed-article:15749921 | pubmed:abstractText | Telomerase reverse transcriptase (hTERT) represents an attractive target for cancer immunotherapy because hTERT is reactivated in most human tumors. A clinical trial was initiated in which hTERT mRNA-transfected dendritic cells (DC) were administered to 20 patients with metastatic prostate cancer. Nine of these subjects received DC transfected with mRNA encoding a chimeric lysosome-associated membrane protein-1 (LAMP) hTERT protein, allowing for concomitant induction of hTERT-specific CD8+ and CD4+ T cell responses. Treatment was well tolerated. Intense infiltrates of hTERT-specific T cells were noted at intradermal injection sites after repeated vaccination. In 19 of 20 subjects, expansion of hTERT-specific CD8+ T cells was measured in the peripheral blood of study subjects, with 0.9-1.8% of CD8+ T cells exhibiting Ag specificity. Patients immunized with the chimeric LAMP hTERT vaccine developed significantly higher frequencies of hTERT-specific CD4+ T cells than subjects receiving DC transfected with the unmodified hTERT template. Moreover, CTL-mediated killing of hTERT targets was enhanced in the LAMP hTERT group, suggesting that an improved CD4+ response could augment a CTL response. Vaccination was further associated with a reduction of prostate-specific Ag velocity and molecular clearance of circulating micrometastases. Our findings provide a rationale for further development of hTERT-transfected DC vaccines in the treatment of prostate and other cancers. | lld:pubmed |
| pubmed-article:15749921 | pubmed:language | eng | lld:pubmed |
| pubmed-article:15749921 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15749921 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:15749921 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15749921 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15749921 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15749921 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15749921 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:15749921 | pubmed:month | Mar | lld:pubmed |
| pubmed-article:15749921 | pubmed:issn | 0022-1767 | lld:pubmed |
| pubmed-article:15749921 | pubmed:author | pubmed-author:DahmPhilippP | lld:pubmed |
| pubmed-article:15749921 | pubmed:author | pubmed-author:ColemanDorisD | lld:pubmed |
| pubmed-article:15749921 | pubmed:author | pubmed-author:DannullJensJ | lld:pubmed |
| pubmed-article:15749921 | pubmed:author | pubmed-author:YanceyDonnaD | lld:pubmed |
| pubmed-article:15749921 | pubmed:author | pubmed-author:NiedzwieckiDo... | lld:pubmed |
| pubmed-article:15749921 | pubmed:author | pubmed-author:GilboaEliE | lld:pubmed |
| pubmed-article:15749921 | pubmed:author | pubmed-author:ViewegJohanne... | lld:pubmed |
| pubmed-article:15749921 | pubmed:author | pubmed-author:BoczkowskiDav... | lld:pubmed |
| pubmed-article:15749921 | pubmed:author | pubmed-author:YangBenjamin... | lld:pubmed |
| pubmed-article:15749921 | pubmed:author | pubmed-author:SuZhenZ | lld:pubmed |
| pubmed-article:15749921 | pubmed:author | pubmed-author:SichiSylviaS | lld:pubmed |
| pubmed-article:15749921 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:15749921 | pubmed:day | 15 | lld:pubmed |
| pubmed-article:15749921 | pubmed:volume | 174 | lld:pubmed |
| pubmed-article:15749921 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:15749921 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:15749921 | pubmed:pagination | 3798-807 | lld:pubmed |
| pubmed-article:15749921 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:15749921 | pubmed:meshHeading | pubmed-meshheading:15749921... | lld:pubmed |
| pubmed-article:15749921 | pubmed:meshHeading | pubmed-meshheading:15749921... | lld:pubmed |
| pubmed-article:15749921 | pubmed:meshHeading | pubmed-meshheading:15749921... | lld:pubmed |
| pubmed-article:15749921 | pubmed:meshHeading | pubmed-meshheading:15749921... | lld:pubmed |
| pubmed-article:15749921 | pubmed:meshHeading | pubmed-meshheading:15749921... | lld:pubmed |
| pubmed-article:15749921 | pubmed:meshHeading | pubmed-meshheading:15749921... | lld:pubmed |
| pubmed-article:15749921 | pubmed:meshHeading | pubmed-meshheading:15749921... | lld:pubmed |
| pubmed-article:15749921 | pubmed:meshHeading | pubmed-meshheading:15749921... | lld:pubmed |
| pubmed-article:15749921 | pubmed:meshHeading | pubmed-meshheading:15749921... | lld:pubmed |
| pubmed-article:15749921 | pubmed:meshHeading | pubmed-meshheading:15749921... | lld:pubmed |
| pubmed-article:15749921 | pubmed:meshHeading | pubmed-meshheading:15749921... | lld:pubmed |
| pubmed-article:15749921 | pubmed:meshHeading | pubmed-meshheading:15749921... | lld:pubmed |
| pubmed-article:15749921 | pubmed:meshHeading | pubmed-meshheading:15749921... | lld:pubmed |
| pubmed-article:15749921 | pubmed:meshHeading | pubmed-meshheading:15749921... | lld:pubmed |
| pubmed-article:15749921 | pubmed:meshHeading | pubmed-meshheading:15749921... | lld:pubmed |
| pubmed-article:15749921 | pubmed:year | 2005 | lld:pubmed |
| pubmed-article:15749921 | pubmed:articleTitle | Telomerase mRNA-transfected dendritic cells stimulate antigen-specific CD8+ and CD4+ T cell responses in patients with metastatic prostate cancer. | lld:pubmed |
| pubmed-article:15749921 | pubmed:affiliation | Genitourinary Cancer Immunotherapy Program, Division of Urology, Duke University Medical Center, Durham, NC 27710, USA. | lld:pubmed |
| pubmed-article:15749921 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15749921 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15749921 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15749921 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15749921 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15749921 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15749921 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15749921 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15749921 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15749921 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15749921 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15749921 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15749921 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15749921 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15749921 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15749921 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15749921 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15749921 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15749921 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15749921 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15749921 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15749921 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15749921 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15749921 | lld:pubmed |
